Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
University of Minnesota Eli Lilly and Company |
---|---|
Information provided by: | University of Minnesota |
ClinicalTrials.gov Identifier: | NCT00275301 |
The overall design of the study is to perform both a PET and MRI scan on objectively identified borderline personality disorder patients, to treat them with olanzapine for 8 weeks, and to then re-scan the patients with PET.
Condition | Intervention |
---|---|
Borderline Personality Disorder |
Drug: olanzapine |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study |
Official Title: | Brain Correlates of Olanzapine Treatment Response in BPD |
Estimated Enrollment: | 15 |
Study Start Date: | December 2005 |
Estimated Study Completion Date: | December 2008 |
Estimated Primary Completion Date: | April 2008 (Final data collection date for primary outcome measure) |
The primary objective of this proposed study will be to compare the baseline PET scan to the endpoint scan in 15 BPD patients who have been treated with olanzapine. The comparison of the scans will be done through a statistical image analysis, using a pixel-by-pixel group mean subtraction strategy with appropriate correction for multiple comparisons. In an exploratory fashion we will compare frontal and temporal regions of interest to address hypotheses of which areas of the brain might show changes with olanzapine treatment.
A secondary objective is to use a normal database to compare the baseline PET scan of the 15 patients in a medication free state to normal subjects. The advantage of this strategy is the ability to closely match subjects by gender and age. As noted earlier, Dr. Pardo has data on 35 control subjects studied on the same scanner we plan to use for this study.
Ages Eligible for Study: | 18 Years to 45 Years |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
United States, Minnesota | |
University of Minnesota, Dept of Psychiatry | |
Minneapolis, Minnesota, United States, 55454 |
Principal Investigator: | S. Charles Schulz, MD | University of Minnesota |
Responsible Party: | University of Minnesota ( S. Charles Schulz, MD ) |
Study ID Numbers: | 0506M70791 |
Study First Received: | January 10, 2006 |
Last Updated: | April 1, 2008 |
ClinicalTrials.gov Identifier: | NCT00275301 History of Changes |
Health Authority: | United States: Institutional Review Board |
Borderline Personality Disorder BPD PET olanzapine brain |
Neurotransmitter Agents Tranquilizing Agents Olanzapine Psychotropic Drugs Central Nervous System Depressants Antiemetics Borderline Personality Disorder |
Antipsychotic Agents Serotonin Uptake Inhibitors Serotonin Mental Disorders Peripheral Nervous System Agents Personality Disorders |
Neurotransmitter Agents Neurotransmitter Uptake Inhibitors Disease Tranquilizing Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Gastrointestinal Agents Psychotropic Drugs Olanzapine Antiemetics Central Nervous System Depressants Borderline Personality Disorder |
Antipsychotic Agents Serotonin Uptake Inhibitors Pharmacologic Actions Serotonin Agents Pathologic Processes Autonomic Agents Mental Disorders Therapeutic Uses Peripheral Nervous System Agents Central Nervous System Agents Personality Disorders |